Table 4.

Overview of multi-omics studies in NASH/NAFLD.

Study Aim	Sample Type	Species	New Data	Data Release	Sample Size	Omics Integration	G	T	P	M	L	MetaG	Reference
C	Liver, serum, fecal samples	Human	Y	Y	n = 10, 7	Data	Y	Y		Y	Y	Y	(Mardinoglu et al., 2018) [124]
C	liver	Mice	Y		n = 9 for TP, n = 6 for scRNAseq	Data and results		Y	Y				(Ægidius et al., 2020) [125]
C	Liver, serum	Human	Y	Y	n = 18 for plasma, n = 9 for liver T			Y	Y	Y			(Wruck et al., 2015) [126]
C	Cell culture	Human	Y		n = 20	Results		Y		Y			(Mesnage et al., 2018) [127]
C	Liver	Rat	Y		n = 10, 10	Results			Y	Y			(Mesnage et al., 2017) [128]
C	Liver, plasma, feces	Mice, human	Y	Y	n = 10 in mice, n = 14 in patients	Data		Y			Y	Y	(Qian et al., 2020) [129]
B	Serum	Human	Y		n = 795 for T2D, n = 2234 for high risk of T2D	Data	Y	Y	Y	Y		Y	(Atabaki-Pasdar et al., 2020) [89]
B	Liver, plasma	Human	Y		n = 576	Data	Y		Y				(Wood et al., 2017) [90]
B	Liver	Mice	Y	Y	n = 48 for liver, n = 16 for plasma	Data and results		Y	Y				(Veyel et al., 2020) [94]
C	Liver	Mice	Y	Y	n = 385	Data	Y	Y	Y				(Jha et al., 2018) [130]
C	Liver	Human, mice				Data		Y	Y				(Lee et al., 2017) [131]
C	Liver, adipose tissue	Mice	Y	Y	n = 228 from 113 mouse strains	Data	Y	Y					(Krishnan et al., 2018) [132]
C	Liver, adipose tissue	Mice				Data	Y	Y					(Kurt et al., 2018) [133]
C	Liver	Human, mice	Y	Y	n = 144 in human, n = 6 in mice	Data and results		Y	Y				(Xiong et al., 2019) [134]

C: characterization; B: biomarker discovery; G: genotyping; T: transcriptomics; P: proteomics; M: metabolomics; L: lipidomics; M: metagenomics. Y: yes.